Activated partial thromboplastin time

Haematology
APTT

This test is also known as the Partial Thromboplastin Time with Kaolin (PTTK) and the Kaolin Cephalin Clotting Time (KCCT) reflecting the methods used to perform the test. The APTT is the main screening test for the Intrinsic clotting system and is the second most common coagulation test being exceeded in frequency only by the prothrombin time. The Partial Thromboplastin of the APTT is a phospholipid extract of animal tissue or from vegetable sources. The phospholipids act as a platelet substitute in the Intrinsic system. The test incorporates an activator, in the absence of added Thromboplastin, which shortens the test and increases the precision and reproducibility by eliminating the variable effects of contact from glass surfaces and by effecting maximum activation. The activator is used to stimulate the production of FXIIa by providing a surface for the function of high molecular weight Kininogen, Kallikrein and FXIIa. The contact activation occurs for a time at 37oC. Calcium is then added to trigger further reactions and the time required for clot formation measured. Standardised Phospholipids are required to form complexes, which activate FX and Prothrombin, which allows the test to be conducted in patient Platelet poor plasma (PPP). The test depends not only on the contact factors and factors VIII and IX, but also on the reactions with factors X, V, Prothrombin and Fibrinogen. It is also sensitive to the presence of circulating anticoagulants (inhibitors) and Heparin.

Preparation of patients: Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase Factor VIII, vWF antigen and fibrinolysis. Veno-occlusion should be avoided.

Precautions: APTT results may be affected by many commonly administered drugs and further studies should be made to determine the source of unexpected abnormal results. Oral contraceptive and Oestrogen therapy in males have been found to decrease APTT in vivo. Conversely, Heparin, Warfarin, Lupus anticoagulant and radio therapy have been found to increase APTT in vivo.

Sample Type:

Sodium Citrate Plasma 3.2%

Temperature: 4 hours Room temperature or 2 weeks -20ºC

Miscellaneous: N/A

Collection: Cf. Special requirement for Coagulation test

Turnaround Time:

24 Hours

Sample Stability:

Whole blood:  4 hours, unless centrifuged at room temperature at 1500g for 15 min, separated and the plasma frozen. Can only be thawed once. If an expected delay from collection time to receipt in the laboratory, suggest send frozen plasma.

(BD Ref. VS5966 Evaluation of 0.109M BD Vacutainer® Plus Plastic and 0.105M BD Vacutainer® Glass Sodium Citrate Tubes for PT and APTT Using the Sysmex CA - 1500 Analyzer. BD, Franklin Lakes, NJ, USA June 2002; CSLI H21- A5)

Instrument / Procedure:

Stago Compact Max, Stago Satellite Max

Units:
Reference Range:

26.0 – 40 seconds

Precautions:

Rejection Criteria: Clotted sample, grossly hemolyzed sample, underfilled/overfilled specimen, unlabeled sample, mismatched patient ID, aged samples >4 hours, wrong sample tube (citrate tube only).

Download full Primary Sample Management Document
Source:

Dacie and Lewis, Practical Haematology 12th edition, 2017

Accreditation Status:
Accredited
Non-Accredited

SAMPLE REQUIREMENTS FOR COAGULATION TESTS

PROCEDURE

Sample Requirements and Collection

  • Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase FVIII, vWF antigen and fibrinolysis. Venous occlusion should be avoided.  
  • Difficult venepuncture with trauma may lead to platelet activation with release of PF4 from alpha granules.
  • Venous blood should be collected into coagulation tubes containing Sodium Citrate 3.2%, 0.105M.
  • Specimens must be mixed immediately post venepuncture to avoid clot activation, by GENTLY inverting the tubes 5 to 10 times.
  • The ratio of whole blood to anticoagulant is crucial to clotting times. A target blood to anticoagulant ratio of 9:1 is optimal.  Under- or over- filled specimens will not be processed this can adversely affect results.  
  • Any warfarin treatment should be mentioned on the request form.
  • Sample rejection Criteria: Clotted sample, grossly hemolyzed sample, underfilled/overfilled specimen, unlabeled sample, mismatched patient ID, aged samples, wrong sample tube (citrate tube only).

Transportation and Storage

  • PT/INR specimens should be transported to the laboratory at room temperature.
  • Coagulation specimens should ideally be analysed within 4 hours of collection. Where this is not possible, centrifuge specimens at room temperature (RT) @ 1500RCF for at least 15 minutes, and then carefully remove the plasma from the cells, transfer to a fresh plastic plain tube and freeze at -20oC.  
  • Non-frozen coagulation specimens should be transported at RT ASAP to avoid deterioration of labile factors V and VIII.
  • Collection of blood through intravenous lines that have been previously flushed with heparin should be avoided. In the event blood is drawn from an indwelling catheter, the line should be flushed with 5ml of saline, and the first 5ml of blood or 6 times the line volume be drawn off and discarded before coagulation tube is filled.
  • Effect of freezing on Coagulation Specimens.
  • A 14days in-house study on the effect of freezing, on coagulation specimens at -20oC, showed that there was negligible and clinically non-significant effect of freezing on coagulation specimen results. Therefore frozen citrated coagulation samples are stable for 14 days at -20oC, post centrifugation. This study is available in-house for reference.
ESR Ref Ranges
Units of Measurement
MALE
FEMALE
>50 Years
mm/hr
0 - ≤12
0 - ≤15
<50 Years
mm/hr
0 - ≤8
0 - ≤10
Download Brochure
Download Sample Report
Analyte
Units of Measurement
MALE
FEMALE
WBC
10^9/L
4.0–10.0
4.0 - 10.0
RBC
10^12/L
5.0 ± 0.5
4.3 ± 0.5
HB
g/dL
15.0 ± 2.0
13.5 ± 1.5
HCT
L/L
0.45 ± 0.05
0.41 ± 0.05
MCV
fL
92 ± 9
92 ± 9
MCH
pg
29.5 ± 2.5
29.5 ± 2.5
MCHC
g/dL
33.0 ± 1.5
33.0 ± 1.5
PLT
10^9/L
280 ± 130
280 ± 130
MPV
fL
N/A
N/A
RDW
%
11.6 - 14.0
11.6 - 14.0
#Neut
10^9/L
2.0 – 7.0
(40 - 80%)
#Lymph
10^9/L
1.0 – 3.0
(20 - 40%)
#Mono
10^9/L
0.2 – 1.0
(2 - 10%)
#Eos
10^9/L
0.02 – 0.5
(1 - 6%)
#Baso
10^9/L
0.02 – 0.1
(<1 - 2%)
Analyte
Units of Measurement
MALE & FEMALE
WBC
10^9/L
Birth: 18 ± 8
Day 3: 15 ± 8
Day 7: 14 ± 8
Day 14: 14 ± 8
1 Month: 12 ± 7
2 Months: 10 ± 5
3–6 Months: 12 ± 6
1 Year: 11 ± 5
2–6 Years: 10 ± 5
6–12 Years: 9 ± 4
RBC
10^12/L
Birth: 6.0 ± 1.0
Day 3: 5.3 ± 1.3
Day 7: 5.1 ± 1.2
Day 14: 4.9 ± 1.3
1 Month: 4.2 ± 1.2
2 Months: 3.7 ± 0.6
3–6 Months: 4.7 ± 0.6
1 Year: 4.5 ± 0.6
2–6 Years: 4.6 ± 0.6
6–12 Years: 4.6 ± 0.6
HB
g/dL
Birth: 18.0 ± 4.0
Day 3: 18.0 ± 3.0
Day 7: 17.5 ± 4.0
Day 14: 16.5 ± 4.0
1 Month: 14.0 ± 2.5
2 Months: 11.2± 1.8
3–6 Months: 12.6 ± 1.5
1 Year: 12.6 ± 1.5
2–6 Years: 12.5 ± 1.5
6–12 Years: 13.5 ± 2.0
HCT
L/L
Birth: 0.60 ± 0.15
Day 3: 0.56 ± 0.11
Day 7: 0.54 ± 0.12
Day 14: 0.51 ± 0.12
1 Month: 0.43 ± 0.10
2 Months: 0.35 ± 0.07
3–6 Months: 0.35 ± 0.08
1 Year: 0.34 ± 0.04
2–6 Years: 0.37 ± 0.03
6–12 Years: 0.40 ± 0.05
MCV
fL
Birth: 110 ± 10
Day 3: 105 ± 13
Day 7: 107 ± 19
Day 14: 105 ± 19
1 Month: 104 ± 12
2 Months: 95 ± 8
3–6 Months: 76 ± 8
1 Year: 78 ± 6
2–6 Years: 81 ± 6
6–12 Years: 86 ± 9
MCH
pg
Birth: 34 ± 3
Day 3: 34 ± 3
Day 7: 34 ± 3
Day 14: 34 ± 3
1 Month: 33 ± 3
2 Months: 30 ± 3
3–6 Months: 27 ± 3
1 Year: 27 ± 2
2–6 Years: 27 ± 3
6–12 Years: 29 ± 4
MCHC
g/dL
Birth: 33.0 ± 3.0
Day 3: 33.0 ± 4.0
Day 7: 33.0 ± 5.0
Day 14: 33.0 ± 5.0
1 Month: 33.0 ± 4.0
2 Months: 32.0 ± 3.5
3–6 Months: 33.0 ± 3.0
1 Year: 34.0 ± 2.0
2–6 Years: 34.0 ± 3.0
6–12 Years: 34.0 ± 3.0
PLT
10^9/L
Birth: 100 – 450
Day 3: 210 – 500
Day 7: 160 – 500
Day 14: 170 – 500
1 Month: 200 – 500
2 Months: 210 – 650
3–6 Months: 200 – 550
1 Year: 200 – 550
2–6 Years: 200 – 490
6–12 Years: 170 – 450
Reticulocytes
10^9/L
Birth: 120 – 400
Day 3: 50 – 350
Day 7: 50 – 100
Day 14: 50 - 100
1 Month: 20 – 60
2 Months: 30 – 50
3–6 Months: 40 – 100
1 Year: 30 – 100
2–6 Years: 30 – 100
6–12 Years: 30 – 100
#Neut
10^9/L
Birth: 4 – 14
Day 3: 3 – 5
Day 7: 3 – 6
Day 14: 3 – 7
1 Month: 3 – 9
2 Months: 1.0 – 5
3–6 Months: 1 – 6
1 Year: 1 – 7
2–6 Years: 1.5 – 8
6–12 Years: 2 – 8
#Lymph
10^9/L
Birth: 3 – 8
Day 3: 2 – 8
Day 7: 3 – 9
Day 14: 3 – 9
1 Month: 3 – 16
2 Months: 4 – 10
3–6 Months: 4 – 12
1 Year: 3.5 – 11
2–6 Years: 6 - 9
6–12 Years: 1 - 5
#Mono
10^9/L
Birth: 0.5 – 2.0
Day 3: 0.5 – 1.0
Day 7: 0.1 – 1.7
Day 14: 0.1 – 1.7
1 Month: 0.3 – 1.0
2 Months: 0.4 – 1.2
3–6 Months: 0.2 – 1.2
1 Year: 0.2 – 1.0
2–6 Years: 0.2 – 1.0
6–12 Years: 0.2 – 1.0
#Eos
10^9/L
Birth: 0.1 – 1.0
Day 3: 0.1 – 2.0
Day 7: 0.1 – 0.8
Day 14: 0.1 – 0.9
1 Month: 0.2 – 1.0
2 Months: 0.1 – 1.0
3–6 Months: 0.1 – 1.0
1 Year: 0.1 – 1.0
2–6 Years: 0.1 – 1.0
6–12 Years: 0.1 – 1.0
Reference Ranges:
Age
Absolute Reference Range
Age
% Reference Range
0 - 1 day
324 - 617 x109/L
0 - 1 day
1.72 - 8.62%
1 - 5 days
85 - 400 x109/L
1 - 5 days
1.9 - 9.1%
5 days - 1 mth
34.2 - 724 x109/L
5 days - 1 mth
0.1 - 6.9%
1 - 3 mths
21.3 - 205 x109/L
1 - 3 mths
0.1 - 6.27%
3 - 12 mths
8.0 - 171 x109/L
3 - 12 mths
0.1 - 4.7%
1 - 3 yrs
55.6 - 120 x109/L
1 - 3 yrs
0.35 - 2.95%
3 - 7yrs
16.4 - 120.7 x109/L
3 - 7yrs
0.25 - 2.57%
Adult
35.2 - 122.8 x109/L
Adult
0.75 - 2.7%
Contact Us!

Related Tests

Related Tests

Related Tests

Related Tests